Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?

Inhibitors of the protease dipeptidyl peptidase IV (DPP-IV) are promising new drugs for the treatment of type 2 diabetes. They are thought to act by inhibiting the breakdown of glucagon-like peptide-1 and, thereby, selectively enhancing insulin release under conditions when it is physiologically req...

Descripción completa

Detalles Bibliográficos
Autores principales: Michel, Martin C., Fliers, Eric, Van Noorden, Cornelis J. F.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2008
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323035/
https://www.ncbi.nlm.nih.gov/pubmed/18398599
http://dx.doi.org/10.1007/s00210-008-0280-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323035/
https://www.ncbi.nlm.nih.gov/pubmed/18398599
http://dx.doi.org/10.1007/s00210-008-0280-0

Ejemplares similares